Search results for: Determining Value
Filter search results
Spotlight on OHE: Innovation, Regulation and Antibiotics
30 September 2014
…the value of an innovation, not the patient. The cost and risk in drug development are high. To determine how best to target its R&D efforts, the pharmaceutical industry needs…
OHE at ISPOR Europe: Presentations
19 November 2014
…The Netherlands. What Value Do We Place on a Cure? Value Demonstration Challenges Associated with Innovator and Regenerative Therapies in the EU, North America, and Asia. Moderator: Eric C Faulkner…
What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?
1 February 2017
…values. We begin by providing examples of the importance and implications of the… The aim of this paper is to consider what normative arguments might exist for advocating the use…
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
14 October 2025
…1990s. She warned that there is an ever-increasing wedge between cost effectiveness, social value, and affordability. She pointed out that there are current pipelines of high-value therapies with huge upfront…
Prevention pays off – so why aren’t we doing more of it?
5 June 2025
…on child immunisation delivery, but seem to be overlooking the value of adult immunisations. In the UK for example, the adult immunisation framework is limited to only 5 out of 18 possible…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…work for payers with a fixed budget? If the rewards are linked to value, how would the budget impact on payers differ from Value-Based Pricing? Might retroactive adjustment be needed?…
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
…relaunch the initiative, included a mismatch between the number of successful innovation passports (IP) granted at the start of the pathway and the capacity to deliver the best value to…
The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
1 February 2012
…the benefits and weaknesses of such schemes; and consider their value as an incentive for innovation. In the literature to date, the authors note, identified benefits are countered by significant…
New ISPOR Task Force Report on Multiple Criteria Decision Analysis
9 February 2016
Professor Nancy Devlin co-chaired the ISPOR task force on uses of MCDA in health care decision making. The first report from the task force has just been published in Value…